One of the pioneers and leading entrepreneurs in the development of personalised cancer vaccines is Professor Ugur Sahin.
In addition to being CEO of the privately-held biopharmaceutical company, BioNTech, he holds an academic appointment at the University of Mainz and is Managing Director of the translational research institute TRON.
This makes Mainz the perfect location for a cancer immunotherapy conference. It’s also where the Association for Cancer Immunotherapy (CIMT) is located. They were the local organisers of the 3rd annual CRI-CIMT-EATI-AACR cancer immunotherapy conference that we recently attended along with over 1400 people from around the world.
One of the underlying themes of the meeting and the posters was the development of personalised cancer vaccines, which is why we’re doing an extended mini-series based on interviews we did in Germany with leaders in the field.
Prof Sahin is a busy man, but we tracked him down in the poster hall. Here’s a brief excerpt from the impromptu interview he kindly gave to BSB.